Alnylam Pharmaceuticals' Non Operating Income fell 306.24% to -$129.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$296.6 million, marking a year-over-year decrease of 123.08%. This contributed to the annual value of -$200.5 million for FY2024, which is 32.47% down from last year.
As of Q3 2025, Alnylam Pharmaceuticals' Non Operating Income stood at -$129.0 million, which was down 573.38% from -$19.2 million recorded in Q2 2025.
Alnylam Pharmaceuticals' Non Operating Income's 5-year high stood at $19.0 million during Q1 2021, with a 5-year trough of -$147.9 million in Q3 2022.
Its 3-year average for Non Operating Income is -$50.9 million, with a median of -$44.4 million in 2023.
Per our database at Business Quant, Alnylam Pharmaceuticals' Non Operating Income tumbled by 586.37% in 2022 and then spiked by 75.65% in 2023.
Alnylam Pharmaceuticals' Non Operating Income (Quarterly) stood at -$65.7 million in 2021, then spiked by 72.00% to -$18.4 million in 2022, then fell by 15.62% to -$21.3 million in 2023, then crashed by 317.23% to -$88.8 million in 2024, then plummeted by 306.24% to -$129.0 million in 2025.
Its last three reported values are -$129.0 million in Q3 2025, -$19.2 million for Q2 2025, and -$59.7 million during Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value